@article{31e27e52b718446e9e163488edbd632c,
title = "Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission",
keywords = "BCR::ABL1, chronic myeloid leukaemia, ddPCR, measurable residual disease, treatment-free remission",
author = "Liu Lu and Kok, {Chung Hoow} and Phuong Dang and Susan Branford and Saunders, {Verity A.} and Naranie Shanmuganathan and Ross, {David M.} and Hughes, {Timothy P.} and Yeung, {David T.O.}",
note = "Funding Information: Susan Branford is a member of the advisory boards of Qiagen, Novartis, and Cepheid, received honoraria from Qiagen, Novartis, Bristol‐Myers Squibb, Incyte, and Cepheid, and research funding from Novartis; Timothy P. Hughes is a member of advisory boards and has received research funding and honoraria from Novartis and Bristol‐Myers Squibb; David M. Ross received research funding and honoraria from Novartis and Bristol‐Myers Squibb; Naranie Shanmuganathan received research funding from Novartis and honoraria from Takeda; David T. O. Yeung received research funding from Novartis and, Bristol‐Myers Squibb, and honoraria from Novartis and Pfizer, Takeda and Amgen. The remaining authors have no conflict of interest to disclose. Funding Information: This study received support from the National Health and Medical Research Council of Australia 1 138 935. This study also received in‐kind support from Bio‐Rad (laboratory reagents and consumables). ",
year = "2022",
month = aug,
doi = "10.1111/bjh.18277",
language = "English",
volume = "198",
pages = "600--603",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley and Sons Inc.",
number = "3",
}